67NR Syngeneic Model Overview

The 67NR syngeneic model represents the non-metastatic member of the BALB/c-derived 4T1 family of murine mammary carcinoma models. Originating from the same spontaneous mammary tumor as the 4T1 and 4T07 lines, 67NR cells produce locally invasive primary tumors that fail to disseminate to distant organs. This lack of metastatic potential makes the 67NR model uniquely suited for studying primary tumor immunity, early-stage tumor growth kinetics, and the mechanisms governing local immune surveillance in an immunocompetent host.

When implanted orthotopically into the mammary fat pad of BALB/c mice, 67NR cells form moderately growing, non-metastatic tumors with stable histopathology and consistent take rates. The model retains an intact immune microenvironment, allowing detailed evaluation of how immune cells regulate tumor containment and how immunotherapies can modulate local anti-tumor responses without interference from systemic spread. The 67NR system is therefore widely utilized as a baseline model for comparative studies against 4T07 and 4T1, providing a complete immuno-oncology spectrum from non-metastatic to highly metastatic phenotypes.

Request a Custom Quote for 67NR Syngeneic Model

Biological and Molecular Characteristics

The 67NR cell line was established from a spontaneous mammary carcinoma of BALB/c origin and shares a common genetic lineage with 4T1 and 4T07. It exhibits a well-differentiated epithelial morphology and maintains a triple-negative phenotype, lacking expression of ER, PR, and HER2. Unlike its metastatic counterparts, 67NR cells show limited motility and reduced expression of metalloproteinases, contributing to the absence of detectable distant metastases. The cytokine profile of 67NR tumors demonstrates relatively low secretion of inflammatory mediators such as CXCL1 and CCL2, resulting in decreased recruitment of myeloid-derived suppressor cells (MDSCs) and a less immunosuppressive tumor microenvironment.

Parameter	Description
Host strain	BALB/c (female, 6–8 weeks)
Tumor origin	Spontaneous mammary carcinoma (mouse)
Receptor status	ER– / PR– / HER2–
Inoculation route	Orthotopic (mammary fat pad) or subcutaneous
Tumor take rate	>90%
Doubling time	Approximately 4–5 days in vivo
Metastatic potential	Non-metastatic
Immunophenotype	Moderate T-cell infiltration, limited MDSC recruitment
Common applications	Immune surveillance, local tumor immunity, checkpoint inhibition studies

In Vivo Model Development and Tumorigenicity

In vivo establishment of the 67NR model is achieved through orthotopic implantation of tumor cells into the mammary fat pad of BALB/c mice. Tumors typically become palpable within 10 to 14 days following implantation and grow progressively without spontaneous metastasis to distant organs. Subcutaneous inoculation produces similarly reproducible growth and is often selected for studies requiring external measurement or serial sampling.

Because the 67NR line lacks the capacity for vascular or lymphatic dissemination, it offers a controlled platform for assessing immune-mediated tumor rejection, T-cell activation, and the kinetics of local inflammation. The model’s slower growth rate relative to 4T1 allows for extended study duration, which facilitates detailed monitoring of immune infiltration and therapeutic effects over time. The absence of metastatic burden makes 67NR particularly suitable for mechanistic analyses of primary tumor immunity and for evaluating agents designed to enhance local immune control.

Request a Custom Quote for 67NR Syngeneic Model

Histopathology and Immunohistochemical Profile

Microscopic evaluation of 67NR tumors reveals cohesive epithelial nests surrounded by organized fibrous stroma. The tumors are less necrotic and less vascularized than 4T1 or 4T07 lesions, reflecting their limited invasiveness. The tumor margins are well demarcated, and inflammatory cell infiltration is generally moderate, consisting of lymphocytes and macrophages dispersed within the stroma. The overall histological pattern indicates a more differentiated phenotype and reduced cellular plasticity compared to metastatic variants of the same lineage.

Immunohistochemical analysis typically demonstrates moderate Ki-67 expression, reflecting an intermediate proliferative index. PD-L1 expression is present but less pronounced than in 4T1 tumors. CD3 and CD8 staining identify an appreciable population of T lymphocytes within the tumor and peritumoral regions, indicating active immune surveillance. F4/80 staining reveals macrophage infiltration, although these cells appear less polarized toward an immunosuppressive phenotype. The collective immunohistochemical profile of 67NR tumors highlights a more balanced tumor-immune interface, where immune activity and tumor growth coexist in relative equilibrium.

Preclinical Applications and Drug Response

The 67NR syngeneic model provides an essential foundation for understanding the local immune control of tumor growth in the absence of metastasis. It is frequently used to investigate immune checkpoint modulation, macrophage polarization, and the dynamics of T-cell-mediated tumor containment. Because 67NR tumors exhibit limited immune suppression, they serve as a favorable model for assessing early immune activation following checkpoint blockade with PD-1 or CTLA-4 inhibitors. Studies using 67NR also explore cytokine therapy, vaccine-based immunization, and adoptive T-cell transfer, particularly in contexts where systemic immune tolerance has not yet developed.

This model is integral to comparative studies within the 4T1 family, allowing researchers to evaluate how progressive changes in tumor aggressiveness correspond to immune evasion and therapeutic response. The 67NR system, with its non-metastatic behavior and intact immune environment, is especially valuable for mechanistic studies aimed at preventing tumor escape, reinforcing immune surveillance, and establishing long-term immune memory within the primary tumor setting.

Request This Model

To request the 67NR syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.

Request a Custom Quote for 67NR Syngeneic Model